NYSE:THC • US88033G4073
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TENET HEALTHCARE CORP (THC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-03-12 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-17 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-13 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-13 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-12 | UBS | Maintains | Buy -> Buy |
| 2026-02-12 | Keybanc | Maintains | Overweight -> Overweight |
| 2026-02-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-12 | Jefferies | Maintains | Buy -> Buy |
| 2026-02-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-07 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-02 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-21 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-03 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-30 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-29 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-29 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-29 | UBS | Maintains | Buy -> Buy |
| 2025-10-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-10-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 20.564B 7.25% | 20.675B 0.54% | 21.31B 3.07% | 22.239B 4.36% | 22.663B 1.91% | 23.989B 5.85% | 24.52B 2.21% | 26.301B 7.26% | 26.479B 0.68% | 27.583B 4.17% | 28.701B 4.05% | |
| EBITDA YoY % growth | 3.682B 17.71% | 4.044B 9.83% | 4.643B 14.81% | 4.664B 0.45% | 4.763B 2.12% | 5.075B 6.55% | 5.252B 3.49% | 5.486B 4.46% | 5.35B -2.48% | 5.571B 4.13% | 5.795B 4.02% | |
| EBIT YoY % growth | 2.812B 22.96% | 3.226B 14.72% | 3.78B 17.17% | 3.726B -1.43% | 3.768B 1.13% | 3.908B 3.72% | 4.095B 4.79% | 4.312B 5.30% | 4.363B 1.18% | 4.559B 4.49% | 4.757B 4.34% | |
| Operating Margin | 13.67% | 15.60% | 17.74% | 16.75% | 16.63% | 16.29% | 16.70% | 16.39% | 16.48% | 16.53% | 16.57% | |
| EPS YoY % growth | 6.98 2.20% | 11.90 70.49% | 16.78 41.01% | 17.15 2.23% | 17.82 3.88% | 20.65 15.89% | 21.81 5.61% | 20.04 -8.13% | 20.43 1.97% | 23.49 14.98% | 26.11 11.13% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 4.21 -3.55% | 4.29 6.78% | 3.87 4.58% | 4.29 -8.79% | 4.79 13.85% | 4.43 3.24% | 4.07 5.29% | 4.45 3.90% |
| Revenue Q2Q % growth | 5.451B 4.37% | 5.498B 4.31% | 5.589B 5.67% | 5.777B 4.52% | 5.809B 6.57% | 5.825B 5.95% | 5.86B 4.85% | 6.05B 4.73% |
| EBITDA Q2Q % growth | 1.131B -5.28% | 1.16B -13.50% | 1.121B -26.73% | 1.216B -33.55% | 1.237B 9.37% | 1.205B 3.88% | 1.178B 5.08% | 1.269B 4.36% |
| EBIT Q2Q % growth | 890.99M -9.82% | 921.91M -0.55% | 916.67M 2.08% | 1.019B 5.38% | 1.014B 13.81% | 991.75M 7.58% | 978.46M 6.74% | 1.052B 3.24% |
All data in USD
28 analysts have analysed THC and the average price target is 255.33 USD. This implies a price increase of 25.65% is expected in the next year compared to the current price of 203.21.
TENET HEALTHCARE CORP (THC) will report earnings on 2026-04-27, after the market close.
The consensus EPS estimate for the next earnings of TENET HEALTHCARE CORP (THC) is 4.21 USD and the consensus revenue estimate is 5.45B USD.
The number of analysts covering TENET HEALTHCARE CORP (THC) is 28.